STOCK TITAN

OPTIMI HEALTH CORP - OPTHF STOCK NEWS

Welcome to our dedicated page for OPTIMI HEALTH news (Ticker: OPTHF), a resource for investors and traders seeking the latest updates and insights on OPTIMI HEALTH stock.

Optimi Health Corp. (OPTHF) is a leading Health Canada-licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA. The company recently obtained a Drug Establishment Licence (DEL) from Health Canada, confirming compliance with Good Manufacturing Practices (GMP). This allows Optimi to supply MDMA and psilocybin capsules to patients with PTSD and Treatment-Resistant Depression under Australia's Authorized Prescriber Scheme and export to regulated jurisdictions globally. Optimi aims to be the trusted global supplier of safe drug candidates by producing proprietary formulations in its 20,000 square feet facilities in Princeton, BC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
none
Rhea-AI Summary
Optimi Health Corp. has entered into a CAD$1.2 million supply agreement with a private entity focused on mushroom-based therapeutic drugs. The company will cultivate dried GMP psilocybin-containing biomass and extract for distribution to international research sites.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.62%
Tags
-
Rhea-AI Summary

Optimi Health Corp. (OTCQX: OPTHF) has announced a significant long-term distribution agreement with Mind Medicine Australia to supply GMP-grade MDMA and psilocybin for therapeutic use in Australia. This follows the Australian government's reclassification allowing authorized psychiatrists to prescribe these substances for treatment-resistant conditions starting July 1, 2023. Key aspects include signed purchase orders for medical-grade substances manufactured under GMP protocols at Optimi's Health Canada licensed facility. This agreement represents Optimi's first international sales of these products, supporting the push for expanded access to psychedelic therapies in response to the mental health crisis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.25%
Tags
none
-
Rhea-AI Summary

Optimi Health Corp. has submitted a clinical trial application for a Phase I study to evaluate the safety of its natural psilocybin standardized extract and proprietary MDMA drug candidate in healthy therapists. This trial, conducted in collaboration with ATMA Journey Centers, is the first to compare the effects of both substances. The study aims to enroll 25 participants across five groups, assessing safety and physiological markers. The company aims to address the significant shortage of therapists trained in psychedelic therapy as it progresses towards commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.6%
Tags
Rhea-AI Summary

Optimi Health Corp. has announced the successful production of its proprietary MDMA drug candidate, OPTI-MHCL, under Good Manufacturing Practices (GMP) at its facility in Princeton, British Columbia. The drug, which demonstrates a purity of over 99%, is intended for clinical trials and patient access through Health Canada’s Special Access Program and Australia’s Authorized Prescriber Scheme.

Optimi aims to meet the growing global demand for MDMA, particularly with advancements towards FDA approval for MDMA-assisted therapy for PTSD. This end-to-end manufacturing process positions Optimi as a significant supplier in the psychedelics market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.1%
Tags
none
-
Rhea-AI Summary

Optimi Health Corp (OTCQX: OPTHF) announced a significant expansion of its sales network in Canada on January 17, 2023. The company, licensed by Health Canada, produces natural psilocybin and functional mushrooms. Key partnerships have been formed with Purity Life Health Products for distribution and M2 Brand Management as the exclusive retail broker to increase brand presence. Products will be sold online via Amazon.ca and at six Holt Renfrew locations by February 2023. The CEO has emphasized that this expansion is a critical part of their revenue strategy moving forward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
none
-
Rhea-AI Summary

Optimi Health Corp. announces the re-election of five board members following its Annual General Meeting on January 9, 2023. The directors re-elected include Bryan Safarik, Jacob Safarik, Jon Schintler, Dane Stevens, and JJ Wilson. The company also expressed gratitude to outgoing director Michael Stier. Additionally, Smythe LLP was re-appointed as the auditor, and the Company’s Equity Incentive Plan was re-approved. Optimi operates under Health Canada regulations, focusing on natural and synthetic psychedelic substances and functional mushrooms for the wellness market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
management
Rhea-AI Summary

Optimi Health applauds Alberta's decision to regulate psychedelics for therapeutic use, highlighting the importance of a safe supply of psilocybin and MDMA for mental health treatment. Effective January 16, 2023, physicians will be able to prescribe these substances for treatment-resistant conditions. As the largest cultivator of EU-GMP psilocybin and MDMA in North America, Optimi is strategically positioned to support the province's new framework. The company's CEO describes this regulatory move as politically courageous, reaffirming the clinical benefits of psychedelics in addressing mental health challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.1%
Tags
none

FAQ

What is the current stock price of OPTIMI HEALTH (OPTHF)?

The current stock price of OPTIMI HEALTH (OPTHF) is $0.152 as of December 24, 2024.

What is the market cap of OPTIMI HEALTH (OPTHF)?

The market cap of OPTIMI HEALTH (OPTHF) is approximately 14.6M.

What is Optimi Health Corp. specialized in?

Optimi is a Health Canada-licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances like botanical psilocybin and MDMA.

What recent milestone did Optimi achieve?

Optimi obtained a Drug Establishment Licence (DEL) from Health Canada, affirming its compliance with Good Manufacturing Practices (GMP) to supply MDMA and psilocybin capsules for patients.

What is Optimi's goal in the pharmaceutical industry?

Optimi aims to be the top trusted supplier of safe drug candidates globally by producing proprietary formulations in its 20,000 square feet facilities in Princeton, BC.

Where is Optimi's manufacturing facility located?

Optimi's manufacturing facilities totaling 20,000 square feet are located in Princeton, British Columbia.

What licenses does Optimi hold?

Optimi holds a Controlled Drugs and Substances Dealer's Licence and a Drug Establishment Licence (DEL), enabling the production of GMP-grade products and APIs.

How does Optimi plan to support global psychedelic research?

Optimi has completed its first international shipment of MDMA to Israel, supporting global research and innovation in the psychedelic field.

What is Optimi's key achievement in terms of export?

Optimi received the necessary Export Permit from Health Canada, confirming its ability to export controlled substances internationally.

What services does Oak Hill Financial Inc. provide to Optimi?

Oak Hill Financial Inc. provides comprehensive investor relations, business, and capital markets advisory services to Optimi at a rate of CDN$12,000 per month.

How does Optimi plan to expand its shareholder base?

Optimi aims to engage new investors and communicate its corporate milestones effectively through partnerships like Oak Hill Financial Inc.

What makes Optimi unique in the pharmaceutical industry?

Optimi's unique capabilities lie in producing scalable psychedelic formulations for transformational human experiences while meeting the highest quality and safety standards.

OPTIMI HEALTH CORP

OTC:OPTHF

OPTHF Rankings

OPTHF Stock Data

14.58M
58.12M
16.52%
0.05%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Garibaldi Highlands